Business Wire
20 Jul 2026, 08:00 UTC · 10w ago
Verdict
Headline takes no side. We score ALM +0.60 across one claim — strongly bullish.
+0.60strongly bullish
More positive than 78% of ticker scores this week
What the story claims
1 claim · scored −1 bearish … +1 bullish
The European Medicines Agency (EMA) has accepted the submission to extend the Marketing Authorisation Application of Ebglyss (lebrikizumab) to children and adolescents aged 6 months and older.
More positive than 79% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 78% of ticker scores this week
The company's application to expand the treatment use of Ebglyss to children and adolescents was accepted by the EMA.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
2h ago
−4.2%
Price is moving against the score
$13.19 vs $13.77 close before publication (Jul 17) · not market-adjusted
ALM chart →
